Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients

Diabetes

Volumn 54, Issue 3, 2005, Pages 880-885

  Boden, Guenther ^a,c   Homko, Carol ^a   Mozzoli, Maria ^a   Showe, Louise C ^b   Nichols, Calen ^b   Cheung, Peter ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WISTAR INSTITUTE   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN SENSITIZING AGENT; ROSIGLITAZONE; TROGLITAZONE;

ADIPOSE TISSUE; ADULT; AEROBIC METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HYBRIDIZATION; MALE; MUSCLE BIOPSY; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; UPREGULATION;

ADIPOSE TISSUE; BIOLOGICAL TRANSPORT; CHROMANS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FEMALE; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 14644415905     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.3.880     Document Type: Article

References (43)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 270:12953-12956, 1995
3. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
4. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234, 1994
5. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM: Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin dependent diabetes mellitus. J Clin Invest 101:543-548, 1998
6. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007, 1981
7. Santomauro ATMG, Boden G, Silva MER, Rocha DM, Santos RF, Ursich MJM, Strassmann PG, Wajchenberg BL: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836-1841, 1999
8. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46:433-439, 1997
9. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445-450, 2000
10. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hseuh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 128:176-185, 1998
11. Mayerson AB, Hundal RS, Dufour S: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
12. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277, 2001
13. Racette SB, Davis AO, McGill JB, Klein S: Thiazolidinediones enhance insulin-mediated suppression of fatty acid fiux in type 2 diabetes mellitus. Metabolism 51:169-174, 2002
14. Boden G, Cheung P, Mozzoli M, Fried SK: Effect thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52:753-759, 2003
15. Tappy L, Owen OW, Boden G: Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212-1216, 1988
16. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, Virok D, Chang C, Horng WH, Johnson J, Wysocka M, Showe MK, Showe LC: Classification and prediction of survival in patients with the leukemic phase of cutaneous T-cell lymphoma. J Exp Med 197:1477-1488, 2003
17. Abumrad N, el-Maghrabi M, Amri E, Lopez E, Grimaldi P: Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: homology with human CD36. J Biol Chem 268:17665-17668, 1992
18. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272:28210-28217, 1997
19. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J Biol Chem 273:16710-16714, 1998
20. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR: Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285: E354-E362, 2003
21. Brown GC: Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 284:1-13, 1992
22. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurilla E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003
23. Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734, 2001
24. Hajri T, Abumrad NA: Fatty acid transport across membranes: relevance to nutrition and metabolic pathology. Ann Rev Nutr 22:383-415, 2002
25. Ibrahimi A, Bonrn S, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA: Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274:26761-26766, 1999
26. 2 consumption of human adipose tissue. Am J Physiol 256:E467-E474, 1989
27. Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B: Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 278:18785-18790, 2003
28. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51:2005-2010, 2002
29. Martin G, Schoonjans K, Staels B, Auwerz AJ: PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137 (Suppl.):S75-S80, 1998
30. Boden G: A fundamental and clinical text. In Diabetes Mellitus. 3rd Ed. LeRoith DE, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott, Williams, and Wilkins, 2004, p. 979-986
31. Boden G: Free fatty acids (FFA) a link between obesity and insulin resistance. Front Biosci 3:169-175, 1998
32. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
33. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
34. Krssak M, Petersen KF, Dresner A, DiPeitro L, Vogel SM, Rothman DL, Shulman GI, Roden M: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:13-116, 1999
35. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
36. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
37. Okuno A, Tamemotto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
38. deSouza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871, 2001
39. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:784-2791, 2002
40. Ruderman N, Parentki M: AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature 3:340-351, 2004
41. Yang X, Pratley RE, Tokraks S, Bogardus C, Permana PA: Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. Diabetologia 45:1584-1593, 2002
42. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS: Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51:1913-1920, 2002
43. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466-8471, 2003